CSI Market
Sign In | Register

Enlivex Therapeutics Ltd (ENLV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ENLV Annual Cash Flow →
The quarterly cash flow data below helps track how Enlivex Therapeutics Ltd's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-1,235.53
Depreciation & amortization0.33
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets363.19
Share-based Compensation1.78
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction606.78
Interest On Short Term Bank Deposit-
Accrued Income On Deposits-
Issuance Expenses Related To Warrants Exercisable Into Shares-
Changes In Values Of Warrant Exercisable Into Shares Liability-
Noncash Operating Lease Expense-
Gain Loss On Marketable Securities And Shortterm Bank Deposits-
Fair Value Option Changes In Fair Value Gain Loss-
Income taxes382.65
Unrealized Gain (Loss) on Investments310.12
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable, Trade3.00
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities1.08
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.05
Other Working Capital0.00
Other Noncash Income (Expense)-0.26
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.21
Discontinued operations0.00
Net Cash flow from Operating Activities-10.42
Investing Activities
Capital Expenditures0.07
Sale of Capital Items0.00
Short-term Investments Proceeds24.50
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payments To Acquire Short Term Bank Deposit-
Investment In Shortterm Bank Deposits-
Payments For Proceeds From Short Term Bank Deposits-
Net Cash Cash Equivalents And Restricted Cash Received In Issuance Of Shares For Net Assets Of Bioblast Pharma Ltd.-
Purchase Of Digital Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock10.38
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.73
Stock Issued During Period Share Issuance Of Common And Preferred Stock Series A In Connection With Conversion Of Convertible Notes-
Stock Issued During Period Shares Interest On Convertible Notes Value-
Assets Acquired-
Less Liabilities Assumed-
Total Net Assets-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Proceeds From Issuance Of Shares And Warrants Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.38
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.35
Total Cash Flow-1.36
4 historic quarters locked

Sign in to unlock the full Enlivex Therapeutics Ltd cash flow history.

Sign In Create Free Account

About Enlivex Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-033857

Figures are derived from filed reports and may be restated. Historical data is subject to revision.